Identification
- Summary
Nafcillin is a penicillin derivative antibiotic used to treat susceptible staphylococcal infections.
- Generic Name
- Nafcillin
- DrugBank Accession Number
- DB00607
- Background
A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive Staphylococcus aureus infections 1.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Nafcillin (DB00607)
- Weight
- Average: 414.475
Monoisotopic: 414.124942514 - Chemical Formula
- C21H22N2O5S
- Synonyms
- (2-ethoxy-1-naphthalenyl)penicillin
- (2-ethoxy-1-naphthyl)penicillin
- (2S,5R,6R)-6-[(2-ethoxy-1-naphthoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- 6-(2-ethoxy-1-naphthamido)penicillanic acid
- Nafcilina
- Nafcillin
- Nafcilline
- Nafcillinum
- Naphcillin
Pharmacology
- Indication
Indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Bacterial infections •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Nafcillin is a semisynthetic antibiotic substance derived from 6-amino-penicillanic acid. The drugs in this class are highly resistant to inactivation by staphylococcal penicillinase and are active against penicillinase-producing and non penicillinase-producing strains of Staphylococcus species.
- Mechanism of action
Like other penicillins, nafcillin exerts a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication in the bacterial cell wall synthesis Label. It inhibits the biosynthesis of the bacterial cell wall by forming covalent bonds with penicillin-binding proteins that play a critical role in the final transpeptidation process. Binding to penicillin-binding proteins inhibits the transpeptidase and carboxypeptidase activities conferred by these proteins and prevents the formation of the crosslinks 4.
Target Actions Organism APenicillin-binding protein 1b inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 2B inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 2a inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 3 inhibitorStreptococcus pneumoniae APenicillin-binding protein 1A inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) - Absorption
Following intravenous administration of 500mg nafcillin, the mean plasma concentration was approximately 30 µg/mL. This value was reached after 5 minutes of injection Label.
- Volume of distribution
Nafcillin is reported to be widely distributed in various body fluids, including bile, pleural, amniotic and synovial fluids Label.
- Protein binding
The degree of nafcillin binding to serum proteins is 89.9 ± 1.5%, where it is mainly bound to albumin Label.
- Metabolism
Hepatic metabolism accounts for less than 30% of the biotransformation of most penicillins.
- Route of elimination
Nafcillin is primarily eliminated by non-renal routes, namely hepatic inactivation and excretion in the bile.
- Half-life
The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Serious toxicity is unlikely following large doses of nafcillin. Acute ingestion of large doses of nafcillin may cause nausea, vomiting, diarrhea and abdominal pain. Acute oliguric renal failure and hematuria may occur following large doses. The oral LD50 in rats is >5000mg/kg and the intravenous LD50 in rats is >1000mg/kg MSDS.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbemaciclib The metabolism of Abemaciclib can be increased when combined with Nafcillin. Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Nafcillin. Acemetacin Acemetacin may decrease the excretion rate of Nafcillin which could result in a higher serum level. Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Nafcillin. Acetaminophen The metabolism of Acetaminophen can be increased when combined with Nafcillin. - Food Interactions
- Take on an empty stomach. Food may make the absorption of oral nafcillin unpredictable.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Nafcillin sodium 49G3001BCK 985-16-0 OCXSDHJRMYFTMA-KMFBOIRUSA-M - International/Other Brands
- Nallpen / Unipen
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Nafcillin Injection, solution 1 g/50mL Intravenous Baxter Healthcare Corporation 1989-10-31 Not applicable US 
Nafcillin Injection, solution 2 g/100mL Intravenous Baxter Healthcare Corporation 1989-10-31 Not applicable US Unipen Injection Pws 500mg/vial Powder, for solution 500 mg / vial Intramuscular; Intravenous Wyeth Ayerst Canada Inc. 1994-12-31 1998-08-13 Canada 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Nafcillin Injection, powder, for solution 1 g/4mL Intramuscular; Intravenous Sagent Pharmaceuticals 2012-10-25 Not applicable US Nafcillin Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Renaissance Ssa, Llc 2021-12-31 Not applicable US Nafcillin Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Sandoz GmbH 1984-08-02 Not applicable US Nafcillin Injection, powder, for solution 2 g/8mL Intramuscular; Intravenous Eugia US LLC 2012-12-26 Not applicable US Nafcillin Injection, powder, for solution 10 g/100mL Intravenous Fresenius Kabi USA, LLC 2011-04-27 Not applicable US
Categories
- ATC Codes
- J01CR50 — Combinations of penicillins
- J01CR — Combinations of penicillins, incl. beta-lactamase inhibitors
- J01C — BETA-LACTAM ANTIBACTERIALS, PENICILLINS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Amides
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Beta-Lactam Antibacterials
- Beta-Lactamase Resistant Penicillins
- beta-Lactams
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 CYP1A2 Inducers (strength unknown)
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (moderate)
- Cytochrome P-450 CYP3A4 Inducers (strength unknown)
- Cytochrome P-450 Enzyme Inducers
- Heterocyclic Compounds, Fused-Ring
- Lactams
- OAT1/SLC22A6 inhibitors
- Penicillins
- Sulfur Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Dipeptides
- Alternative Parents
- Penicillins / N-acyl-alpha amino acids and derivatives / Naphthalenecarboxamides / Alkyl aryl ethers / Tertiary carboxylic acid amides / Thiazolidines / Secondary carboxylic acid amides / Azetidines / Thiohemiaminal derivatives / Azacyclic compounds show 8 more
- Substituents
- 1-naphthalenecarboxamide / 1-naphthalenecarboxylic acid or derivatives / Alkyl aryl ether / Alpha-amino acid or derivatives / Alpha-dipeptide / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Benzenoid / Beta-lactam show 24 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- penicillin (CHEBI:7447)
- Affected organisms
- Enteric bacteria and other eubacteria
- Staphylococcus aureus
Chemical Identifiers
- UNII
- 4CNZ27M7RV
- CAS number
- 147-52-4
- InChI Key
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N
- InChI
- InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1
- IUPAC Name
- (2S,5R,6R)-6-(2-ethoxynaphthalene-1-amido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- SMILES
- [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O
References
- General References
- Blumenthal KG, Parker RA, Shenoy ES, Walensky RP: Improving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy. Clin Infect Dis. 2015 Sep 1;61(5):741-9. doi: 10.1093/cid/civ394. Epub 2015 May 19. [Article]
- Viehman JA, Oleksiuk LM, Sheridan KR, Byers KE, He P, Falcione BA, Shields RK: Adverse Events Lead to Drug Discontinuation More Commonly among Patients Who Receive Nafcillin than among Those Who Receive Oxacillin. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3090-5. doi: 10.1128/AAC.03122-15. Print 2016 May. [Article]
- Youngster I, Shenoy ES, Hooper DC, Nelson SB: Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting. Clin Infect Dis. 2014 Aug 1;59(3):369-75. doi: 10.1093/cid/ciu301. Epub 2014 Apr 29. [Article]
- 49. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 612). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
- External Links
- Human Metabolome Database
- HMDB0014745
- KEGG Drug
- D08242
- KEGG Compound
- C07250
- PubChem Compound
- 8982
- PubChem Substance
- 46508100
- ChemSpider
- 8634
- BindingDB
- 50103525
- 7233
- ChEBI
- 7447
- ChEMBL
- CHEMBL1443
- ZINC
- ZINC000003875980
- Therapeutic Targets Database
- DAP001166
- PharmGKB
- PA450576
- PDBe Ligand
- NFN
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Nafcillin
- FDA label
- Download (84.8 KB)
- MSDS
- Download (30.2 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Bone Infection / Joint Infection / Osteomyelitis / Prosthetic Joint Infections / Septic Arthritis 1 4 Completed Treatment Skin Diseases, Infectious 1 4 Terminated Treatment Complicated Skin and Skin Structure Infection / Impaired Renal Function / S. Aureus Bacteremia 1 3 Completed Treatment Acute Hematogenous Osteomyelitis 1 3 Terminated Treatment Bacteremia 1
Pharmacoeconomics
- Manufacturers
- Wyeth ayerst laboratories
- Apothecon inc div bristol myers squibb
- Marsam pharmaceuticals llc
- Sandoz inc
- Glaxosmithkline
- Baxter healthcare corp
- Packagers
- Baxter International Inc.
- Cardinal Health
- Mead Johnson and Co.
- Sandoz
- Dosage Forms
Form Route Strength Injection Intramuscular; Intravenous 1 g/1 Injection Intramuscular; Intravenous 2 g/1 Injection, powder, for solution Intramuscular; Intravenous 1 g/1 Injection, powder, for solution Intramuscular; Intravenous 2 g/1 Injection, powder, for solution Intravenous 10 g/100mL Injection, powder, for solution Intravenous 10 g/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 1 g/4mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 2 g/8mL Injection, solution Intravenous 1 g/50mL Injection, solution Intravenous 2 g/100mL Powder, for solution Intramuscular; Intravenous 1 g/1 Powder, for solution Intramuscular; Intravenous 1 g/1g Powder, for solution Intramuscular; Intravenous 2 g/1 Powder, for solution Intramuscular; Intravenous 2 g/2g Injection, powder, for solution Intramuscular; Intravenous 1 g/4mL Injection, powder, for solution Intramuscular; Intravenous 2 g/8mL Injection, powder, for solution Intravenous 1 g/1 Injection, powder, for solution Intravenous 2 g/1 Powder, for solution Intramuscular; Intravenous 500 mg / vial - Prices
Unit description Cost Unit Nafcillin 10 gm vial 118.01USD vial Nafcillin 2 gm vial 24.08USD vial Nafcillin 1 gm vial 12.41USD vial Nafcillin 1 gm/ 50 ml inj 0.43USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Soluble Not Available logP 3.3 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0172 mg/mL ALOGPS logP 3.21 ALOGPS logP 2.29 Chemaxon logS -4.4 ALOGPS pKa (Strongest Acidic) 3.31 Chemaxon pKa (Strongest Basic) -1.9 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 95.94 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 108.14 m3·mol-1 Chemaxon Polarizability 42.22 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.5328 Blood Brain Barrier - 0.9938 Caco-2 permeable - 0.6248 P-glycoprotein substrate Substrate 0.708 P-glycoprotein inhibitor I Non-inhibitor 0.8782 P-glycoprotein inhibitor II Non-inhibitor 0.8807 Renal organic cation transporter Non-inhibitor 0.923 CYP450 2C9 substrate Non-substrate 0.7898 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Non-substrate 0.5 CYP450 1A2 substrate Non-inhibitor 0.8164 CYP450 2C9 inhibitor Non-inhibitor 0.7263 CYP450 2D6 inhibitor Non-inhibitor 0.8869 CYP450 2C19 inhibitor Non-inhibitor 0.8082 CYP450 3A4 inhibitor Inhibitor 0.5653 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7437 Ames test Non AMES toxic 0.796 Carcinogenicity Non-carcinogens 0.6679 Biodegradation Not ready biodegradable 0.9972 Rat acute toxicity 2.1208 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9994 hERG inhibition (predictor II) Non-inhibitor 0.6449
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 209.2569313 predictedDarkChem Lite v0.1.0 [M-H]- 188.24785 predictedDeepCCS 1.0 (2019) [M+H]+ 209.2132313 predictedDarkChem Lite v0.1.0 [M+H]+ 190.64342 predictedDeepCCS 1.0 (2019) [M+Na]+ 208.6395313 predictedDarkChem Lite v0.1.0 [M+Na]+ 196.55595 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transferase activity, transferring acyl groups
- Specific Function
- Not Available
- Gene Name
- pbp1b
- Uniprot ID
- Q7CRA4
- Uniprot Name
- Penicillin-binding protein 1b
- Molecular Weight
- 89479.92 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- Penicillin binding
- Gene Name
- penA
- Uniprot ID
- P0A3M6
- Uniprot Name
- Penicillin-binding protein 2B
- Molecular Weight
- 73872.305 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transferase activity, transferring acyl groups
- Specific Function
- Not Available
- Gene Name
- pbp2a
- Uniprot ID
- Q8DNB6
- Uniprot Name
- Penicillin-binding protein 2a
- Molecular Weight
- 80797.94 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Not Available
- Gene Name
- pbp3
- Uniprot ID
- Q75Y35
- Uniprot Name
- Penicillin-binding protein 3
- Molecular Weight
- 45209.84 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Penicillin binding
- Specific Function
- Cell wall formation.
- Gene Name
- pbpA
- Uniprot ID
- Q8DR59
- Uniprot Name
- Penicillin-binding protein 1A
- Molecular Weight
- 79700.9 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E, Bachmann K: A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97. doi: 10.1124/dmd.108.020701. Epub 2008 May 27. [Article]
- Kim KY, Frey RJ, Epplen K, Foruhari F: Interaction between warfarin and nafcillin: case report and review of the literature. Pharmacotherapy. 2007 Oct;27(10):1467-70. [Article]
- Lang CC, Jamal SK, Mohamed Z, Mustafa MR, Mustafa AM, Lee TC: Evidence of an interaction between nifedipine and nafcillin in humans. Br J Clin Pharmacol. 2003 Jun;55(6):588-90. [Article]
- Abbvie: Venetoclax [Link]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [Article]
Drug created at June 13, 2005 13:24 / Updated at December 02, 2023 06:53